Live Breaking News & Updates on Prnewswire Tyra Biosciences Inc

Stay updated with breaking news from Prnewswire tyra biosciences inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Tyra Biosciences to Present at Upcoming Investor Conferences

/PRNewswire/ Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that. ....

Tyra Biosciences , Todd Harris , Tyra Biosciences Inc , Prnewswire Tyra Biosciences Inc , Fibroblast Growth Factor Receptor , Annual Oncology Innovation Summit , Global Healthcare Conference , Annual Goldman Sachs Global Healthcare Conference ,

Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference

/PRNewswire/ Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that. ....

Todd Harris , Tyra Biosciences , Tyra Biosciences Inc , Prnewswire Tyra Biosciences Inc , Healthcare Life Sciences Conference On , Fibroblast Growth Factor Receptor , Annual Healthcare Life Sciences Conference ,

Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference

CARLSBAD, Calif., Feb. 7, 2024 /PRNewswire/ Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large. ....

Todd Harris , Amy Conrad , Tyra Biosciences , Tyra Biosciences Inc , Healthcare Life Sciences Conference On , Prnewswire Tyra Biosciences Inc , Fibroblast Growth Factor Receptor , Annual Healthcare Life Sciences Conference ,

Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia

CARLSBAD, Calif., Feb. 1, 2024 /PRNewswire/ Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300, an oral FGFR3 selective inhibitor, for the treatment of achondroplasia. Achondroplasia is the most ....

Drug Administration , Prnewswire Tyra Biosciences Inc , Fibroblast Growth Factor Receptor , Achondroplasia Pediatric Treatment Fgfr3 Article Biosciences By Designation Disease Fda For Of Rare Receives The Tyra ,

Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing

/PRNewswire/ Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that. ....

United States , Todd Harris , Tyra Biosciences , Exchange Commission , Prnewswire Tyra Biosciences Inc , Tyra Biosciences Inc , Nextech Invest Ltd , Fibroblast Growth Factor Receptor , Boxer Capital , Securities Act , Private Securities Litigation Reform Act ,